L
Lexaria Bioscience Corp. (LEXX)
NCM – Real Time Price. Currency in USD
0.58
-0.03 (-4.63%)
At close: May 12, 2026, 4:00 PM EDT
0.60
+0.03 (4.66%)
Pre-market: May 13, 2026, 4:00 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.58
-0.03 (-4.63%)
At close: May 12, 2026, 4:00 PM EDT
0.60
+0.03 (4.66%)
Pre-market: May 13, 2026, 4:00 AM EDT
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company’s DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
| Name | Position |
|---|---|
| Dr. C. Michael Gibson M.D., M.S. | Chief Medical Advisor & Member of Scientific Advisory Board |
| Mr. John M. Docherty M.Sc. | Chairman of the Scientific Advisory Board, Chief Scientific Officer, President & Director |
| Mr. Michael Shankman CPA | Chief Financial Officer |
| Mr. Richard C. Christopher | CEO & Director |
| Ms. Kristin Hamilton | Director of Operations |
| Ms. Vanessa Carle | Head of Legal |
| Date | Type | Document |
|---|---|---|
| 2026-04-13 | 10-Q | lxrp_10q.htm |
| 2026-02-06 | 8-K | lxrp_8k.htm |
| 2026-01-28 | 8-K | lxrp_8k.htm |
| 2026-01-13 | 10-Q | lxrp_10q.htm |
| 2025-12-29 | S-1 | lxrp_s1.htm |
| 2025-12-19 | D | |
| 2025-12-10 | DEF 14A | lxrp_def14a.htm |
| 2025-12-05 | POS AM | lxrp_posam.htm |
| 2025-12-05 | CORRESP | filename1.htm |
| 2025-11-28 | 10-K | lxrp_10k.htm |